ReviewCancers2022
The Lung Microbiota and Lung Cancer: A Growing Relationship.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 35 citations in OpenAlex.
- Review
- Microbial Influence on Immune Checkpoint Inhibitor Therapy in Non-Small Cell Carcinoma: The Gut-Lung-Immune Axis.Cancers · 2026Review
- Lower respiratory microbiota as modulators of tumor immunity in lung adenocarcinoma.BMC immunology · 2026Article
- The Gut-Lung Microbiome Crosstalk and Pulmonary Disease.Biomolecules · 2026Review
- Lung microbiota analysis in early-stage lung adenocarcinoma.Microbiology spectrum · 2026Article
- Repurposing of the Macrolide Antibiotic Clarithromycin for the Prevention of Lung Cancer.Molecular cancer therapeutics · 2026Article
- Microbiome modulation of tumorigenesis and immune responses.Journal of biomedical science · 2026Review
- Metabolism-Driven Modulation by the Human Microbiota: Implications for Cancer Therapy and Emerging Strategies.Advances in experimental medicine and biology · 2026Review
- Gut-Lung Microbiota Axis Shapes the Immune Microenvironment and Immunotherapeutic Response in Lung Cancer.International journal of biological sciences · 2026Review
- Artificial intelligence can match domain experts in evidence extraction and critical appraisal of microbial oncogenesis research publications.Frontiers in cellular and infection microbiology · 2026Article
- The interplay of the microbiome and breast cancer: beyond the gut: a narrative review.Annals of medicine and surgery (2012) · 2025Review
- Emerging Techniques of Translational Research in Immuno-Oncology: A Focus on Non-Small Cell Lung Cancer.Cancers · 2025Review
- Microbial biomarker development for detection and prognosis of early-stage non-small cell lung cancer.Cancer biomarkers : section A of Disease markers · 2025Review
- The Role of Eosinophils, Eosinophil-Related Cytokines and AI in Predicting Immunotherapy Efficacy in NSCLCBiomolecules · 2025Review
- Unlocking the secrets of the human gut microbiota: Comprehensive review on its role in different diseases.World journal of gastroenterology · 2025Review
- Exploring the prognostic role of microbial and genetic markers in lung squamous cell carcinoma.Scientific reports · 2025Article
- Research status of the relationship between microecological imbalance and lung cancer.Frontiers in microbiology · 2025Review
- Microbial hallmarks of the respiratory tract in lung cancer: a meta-analysis.Frontiers in microbiomes · 2025Article
- Microbiota as diagnostic biomarkers: advancing early cancer detection and personalized therapeutic approaches through microbiome profiling.Frontiers in immunology · 2025Review
- Ferroptosis as a promising targeted therapy for triple negative breast cancer.Breast cancer research and treatment · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The lung is home to a dynamic microbial population crucial to modulating immune balance. Interest in the role of the lung microbiota in disease pathogenesis and treatment has exponentially increased. In lung cancer, early studies suggested an important role of dysbiosis in tumor initiation and progression. These results have helped accelerate research into the lung microbiota as a potential diagnostic marker and therapeutic target. Microbiota signatures could represent diagnostic biomarkers of early-stage disease. Lung microbiota research is in its infancy with a limited number of studies and only single-center studies with a significant methodological variation. Large, multicenter longitudinal studies are needed to establish the clinical potential of this exciting field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.